Skip to main content
Top
Published in: Clinical Reviews in Allergy & Immunology 1/2018

01-02-2018

Current Perspectives on Erythema Multiforme

Authors: Marianne Lerch, Carlo Mainetti, Benedetta Terziroli Beretta-Piccoli, Thomas Harr

Published in: Clinical Reviews in Allergy & Immunology | Issue 1/2018

Login to get access

Abstract

Recognition and timely adequate treatment of erythema multiforme remain a major challenge. In this review, current diagnostic guidelines, potential pitfalls, and modern/novel treatment options are summarized with the aim to help clinicians with diagnostic and therapeutic decision-making. The diagnosis of erythema multiforme, that has an acute, self-limiting course, is based on its typical clinical picture of targetoid erythematous lesions with predominant acral localization as well as histological findings. Clinically, erythema multiforme can be differentiated into isolated cutaneous and combined mucocutaneous forms. Atypical erythema multiforme manifestations include lichenoid or granulomatous lesions as well as lesional infiltrates of T cell lymphoma and histiocytes. Herpes simplex virus infection being the most common cause, other infectious agents like—especially in children—Mycoplasma pneumoniae, hepatitis C virus, Coxsackie virus, and Epstein Barr virus may also trigger erythema multiforme. The second most frequently identified cause of erythema multiforme is drugs. In different studies, e.g., allopurinol, phenobarbital, phenytoin, valproic acid, antibacterial sulfonamides, penicillins, erythromycin, nitrofurantoin, tetracyclines, chlormezanone, acetylsalicylic acid, statins, as well as different TNF-α inhibitors such as adalimumab, infliximab, and etanercept were reported as possible implicated drugs. Recently, cases of erythema multiforme associated with vaccination, immunotherapy for melanoma, and even with topical drugs like imiquimod have been described. In patients with recurrent herpes simplex virus-associated erythema multiforme, the topical prophylactic treatment with acyclovir does not seem to prevent further episodes of erythema multiforme. In case of resistance to one virostatic drug, the switch to an alternative drug, and in patients non-responsive to virostatic agents, the use of dapsone as well as new treatment options, e.g., JAK-inhibitors or apremilast, might be considered.
Literature
5.
go back to reference Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schroder W, Roujeau JC (2002) Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 138(8):1019–1024CrossRefPubMed Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schroder W, Roujeau JC (2002) Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 138(8):1019–1024CrossRefPubMed
8.
go back to reference Aurelian L, Ono F, Burnett J (2003) Herpes simplex virus (HSV)-associated erythema multiforme (HAEM): a viral disease with an autoimmune component. Dermatol Online J 9(1):1PubMed Aurelian L, Ono F, Burnett J (2003) Herpes simplex virus (HSV)-associated erythema multiforme (HAEM): a viral disease with an autoimmune component. Dermatol Online J 9(1):1PubMed
20.
go back to reference Shabahang L (2010) Characteristics of adult outpatients with erythema multiforme. Pak J Biol Sci: PJBS 13(22):1106–1109CrossRefPubMed Shabahang L (2010) Characteristics of adult outpatients with erythema multiforme. Pak J Biol Sci: PJBS 13(22):1106–1109CrossRefPubMed
22.
go back to reference Monastirli A, Pasmatzi E, Badavanis G, Tsambaos D (2017) Erythema multiforme following pneumococcal vaccination. Acta Dermatovenerol Alp Pannonica Adriat 26(1):25–26PubMed Monastirli A, Pasmatzi E, Badavanis G, Tsambaos D (2017) Erythema multiforme following pneumococcal vaccination. Acta Dermatovenerol Alp Pannonica Adriat 26(1):25–26PubMed
25.
go back to reference Nomura H, Takahashi H, Suzuki S, Kurihara Y, Chubachi S, Kawada I, Yasuda H, Betsuyaku T, Amagai M, Funakoshi T (2017) Unexpected recalcitrant course of drug-induced erythema multiforme-like eruption and interstitial pneumonia sequentially occurring after nivolumab therapy. J Dermatol 44(7):818–821. https://doi.org/10.1111/1346-8138.13810 CrossRefPubMed Nomura H, Takahashi H, Suzuki S, Kurihara Y, Chubachi S, Kawada I, Yasuda H, Betsuyaku T, Amagai M, Funakoshi T (2017) Unexpected recalcitrant course of drug-induced erythema multiforme-like eruption and interstitial pneumonia sequentially occurring after nivolumab therapy. J Dermatol 44(7):818–821. https://​doi.​org/​10.​1111/​1346-8138.​13810 CrossRefPubMed
27.
go back to reference Yanes DA, Kaffenberger JA, Carr DR (2017) Erythema multiforme as a reaction to imiquimod 5% cream. Dermatol Online J 23(2) Yanes DA, Kaffenberger JA, Carr DR (2017) Erythema multiforme as a reaction to imiquimod 5% cream. Dermatol Online J 23(2)
28.
go back to reference Gehanno JF, Priot AE, Balguerie X, Caillard JF (2006) Polyhexamethylenebiguanide hydrochloride exposure and erythema multiforme in a physician. Int J Occup Med Environ Health 19(1):81–82CrossRefPubMed Gehanno JF, Priot AE, Balguerie X, Caillard JF (2006) Polyhexamethylenebiguanide hydrochloride exposure and erythema multiforme in a physician. Int J Occup Med Environ Health 19(1):81–82CrossRefPubMed
32.
go back to reference Begolli Gerqari AM, Ferizi M, Halimi S, Daka A, Hapciu S, Begolli IM, Begolli M, Hysen Gerqari I (2016) Erythema exsudativum multiforme induced by a taurine-containing energy drink. Acta Dermatovenerol Alp Pannonica Adriat 25(4):83–84PubMed Begolli Gerqari AM, Ferizi M, Halimi S, Daka A, Hapciu S, Begolli IM, Begolli M, Hysen Gerqari I (2016) Erythema exsudativum multiforme induced by a taurine-containing energy drink. Acta Dermatovenerol Alp Pannonica Adriat 25(4):83–84PubMed
36.
go back to reference Lee A, Batra P, Furer V, Cheung W, Wang N, Franks A Jr (2009) Rowell syndrome (systemic lupus erythematosus + erythema multiforme). Dermatol Online J 15(8):1PubMed Lee A, Batra P, Furer V, Cheung W, Wang N, Franks A Jr (2009) Rowell syndrome (systemic lupus erythematosus + erythema multiforme). Dermatol Online J 15(8):1PubMed
37.
go back to reference Duarte AF, Mota A, Pereira M, Baudrier T, Azevedo F (2008) Rowell syndrome—case report and review of the literature. Dermatol Online J 14(3):15 Duarte AF, Mota A, Pereira M, Baudrier T, Azevedo F (2008) Rowell syndrome—case report and review of the literature. Dermatol Online J 14(3):15
41.
go back to reference Czarnecka-Operacz M, Jenerowicz D, Szulczynska-Gabor J, Teresiak-Mikolajczak E, Szyfter-Harris J, Bowszyc-Dmochowska M (2016) Vesicular contact reaction may progress into erythema multiforme. Acta Dermatovenerol Croat: ADC 24(4):307–309PubMed Czarnecka-Operacz M, Jenerowicz D, Szulczynska-Gabor J, Teresiak-Mikolajczak E, Szyfter-Harris J, Bowszyc-Dmochowska M (2016) Vesicular contact reaction may progress into erythema multiforme. Acta Dermatovenerol Croat: ADC 24(4):307–309PubMed
44.
go back to reference Elm MK, Murchland MR (2012) Multifocal, fixed-drug eruption masquerading as recurrent erythema multiforme. J Drugs Dermatol: JDD 11(2):244–246PubMed Elm MK, Murchland MR (2012) Multifocal, fixed-drug eruption masquerading as recurrent erythema multiforme. J Drugs Dermatol: JDD 11(2):244–246PubMed
45.
go back to reference Beer K, Beer MS, Appelbaum D (2013) Granuloma annulare masquerading as erythema multiforme. J Drugs Dermatol: JDD 12(6):694–697PubMed Beer K, Beer MS, Appelbaum D (2013) Granuloma annulare masquerading as erythema multiforme. J Drugs Dermatol: JDD 12(6):694–697PubMed
48.
go back to reference Chua SH, Giam YC, Sim CS (1996) Systemic lupus erythematosus with erythema multiforme-like lesions and histiocytic necrotizing lymphadenitis—a case report. Ann Acad Med Singap 25(4):599–601PubMed Chua SH, Giam YC, Sim CS (1996) Systemic lupus erythematosus with erythema multiforme-like lesions and histiocytic necrotizing lymphadenitis—a case report. Ann Acad Med Singap 25(4):599–601PubMed
50.
go back to reference Rzany B, Mockenhaupt M, Baur S, Schroder W, Stocker U, Mueller J, Hollander N, Bruppacher R, Schopf E (1996) Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. J Clin Epidemiol 49(7):769–773. https://doi.org/10.1016/0895-4356(96)00035-2 CrossRefPubMed Rzany B, Mockenhaupt M, Baur S, Schroder W, Stocker U, Mueller J, Hollander N, Bruppacher R, Schopf E (1996) Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. J Clin Epidemiol 49(7):769–773. https://​doi.​org/​10.​1016/​0895-4356(96)00035-2 CrossRefPubMed
51.
go back to reference Ackerman AB, Penneys NS, Clark WH (1971) Erythema multiforme exudativum: distinctive pathological process. Br J Dermatol 84(6):554–566CrossRefPubMed Ackerman AB, Penneys NS, Clark WH (1971) Erythema multiforme exudativum: distinctive pathological process. Br J Dermatol 84(6):554–566CrossRefPubMed
56.
go back to reference Tatnall FM, Schofield JK, Leigh IM (1995) A double-blind, placebo-controlled trial of continuous acyclovir therapy in recurrent erythema multiforme. Br J Dermatol 132(2):267–270CrossRefPubMed Tatnall FM, Schofield JK, Leigh IM (1995) A double-blind, placebo-controlled trial of continuous acyclovir therapy in recurrent erythema multiforme. Br J Dermatol 132(2):267–270CrossRefPubMed
63.
go back to reference Sen P, Chua SH (2004) A case of recurrent erythema multiforme and its therapeutic complications. Ann Acad Med Singap 33(6):793–796PubMed Sen P, Chua SH (2004) A case of recurrent erythema multiforme and its therapeutic complications. Ann Acad Med Singap 33(6):793–796PubMed
68.
go back to reference Chen T, Levitt J, Geller L (2017) Apremilast for treatment of recurrent erythema multiforme. Dermatol Online J 23(1) Chen T, Levitt J, Geller L (2017) Apremilast for treatment of recurrent erythema multiforme. Dermatol Online J 23(1)
Metadata
Title
Current Perspectives on Erythema Multiforme
Authors
Marianne Lerch
Carlo Mainetti
Benedetta Terziroli Beretta-Piccoli
Thomas Harr
Publication date
01-02-2018
Publisher
Springer US
Published in
Clinical Reviews in Allergy & Immunology / Issue 1/2018
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-017-8667-7

Other articles of this Issue 1/2018

Clinical Reviews in Allergy & Immunology 1/2018 Go to the issue